Упрощенная HTML-версия
140
149.
Palkhivala A. Even very low-grade albuminuria is risk factor for CVD / A.
Palkhivala // Электронныйресурс -2005. – Режимдоступа:
www/medscape.com/viewarticle/538770.
150.
Pasumarthy L. Nonalcoholic steatohepatitis: a review of the literature and
updates in management / L. Pasumarthy, J. Srour // South Med. J. – 2010. –
Vol. 103, № 6. – P. 547-550.
151.
Pharmacological inhibition of CB1cannabinoid receptor protects against
doxorubicin-induced cardiotoxicity / P. Mukhopadhyay [et al.] // J. Am.
Coll. Cardiol. – 2007. – Vol. 50. – P. 528-536.
152.
Prediction of lifetime risk for cardiovascular disease by risk factor burden
at 50 years of age / D. M. Lloyd-Jones [et al.] // Circulation. – 2006. – Vol.
113. – P. 791-798.
153.
Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in
mice / А. Riad [et al.] // Cancer Res. – 2009. – Vol. 69, № 2. – P. 695-699.
154.
Rabelink T. J. Endothelial activation and circulating markers of endothelial
activation in kidney disease / T. J.Rabelink, H. C. de Boer, A. J. van
Zonneveld // Nat. Rev. Nephrol. – 2010. – Vol. 6, № 7. – P. 404-414.
155.
Rabinovitch R. Double helix of breast cancer therapy: Intertwining the
Halsted and Fisher hypotheses / R. Rabinovitch, B. Kavanagh // J. Clin.
Oncol. – 2009. – Vol. 27, № 15. – Р. 2422-2423.
156.
Risk of new primary nonbreast cancers after breast cancer treatment: a
Dutch population–based study / M. Schaapveld [et al.] // J. Clin. Oncol. –
2008. – Vol. 26. – P. 1239-1246.
157.
Role of superoxide, nitric oxide and peroxynitrite in doxorubicin-induced
cell death in vivo and in vitro / Р. Mukhopadhyay [et al.] // Am. J. Physiol.
Heart Circ. Physiol. – 2009. – Vol. 296, № 5. – P. 1466-1483.
158.
Sandri M. T. N-terminal pro-B-type natriuretic peptide after high-
dosechemotherapy: a marker predictive of cardiac dysfunction? / M. T.
Sandri, M. Salvatici, D. Cardinaleetal // Clin. Chem. – 2005. – Vol. 51
,
№
8. – P. 1405.